In the chronic colitis model, olsalazine + CBD again improved glycaemic control and plasma GLP-1 but had no effect on colonic GLP-1; conversely, CSA + CBD increased colonic GLP-1 without impacting systemic levels or glucose. This evidence concerns the gene GLP1R and Chronic colitis.